The company, called the Mark Cuban Cost Plus Drug Company, said the aim of the PBM is to be more transparent about drug costs and share more savings with customers, according to the Journal.
The PBM will start bidding for clients next year and hopes to be operational in 2023, Alex Oshmyansky, MD, PhD, the CEO of the Mark Cuban Cost Plus Drug Company, told the Journal. The PBM plans to share the details of its operating costs with clients and will share 100 percent of the rebates they receive from drugmakers.
“The supply chain for distributing pharmaceuticals to patients is so cumbersome and broken,” Dr. Oshmyansky told the Journal. “We decided the only way to get our drugs to the people who need them is to build a parallel supply chain where we have control of all the intermediary players and ensure the same level of transparency at every level.”
The Mark Cuban Cost Plus Drug Company tweeted Oct. 18 looking for a PBM sales leader to join its team, saying, “We hate PBMs. Want to help us build a better one?”
Mark Cuban launched his drug company in January, saying it is dedicated to producing low-cost versions of high-cost generic drugs and pledging to “provide radical transparency in how we price our drugs.”
Currently, nearly 80 percent of prescriptions in the U.S. are managed by three PBMs, CVS Caremark, Express Scripts and OptumRx, the Journal reported.
Read the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
